Report
Industry leaders are embracing biosolutions, this exclusive Capgemini survey reveals that 96% of organisations are already embracing the disruption of biosolutions with about half expecting this transformation within the next five years.
Deep tech advances in AI and LLMs are making this engineering biology a reality. With many businesses engaging in experimentation, pilots, or scaled deployments, the next challenge is moving to full-scale commercial adoption.
This exclusive report explores:
- The applications of engineering biology by industry
- How to capture the sustainability benefits of engineering biology
- Insights from 1,600 executives on the barriers to adoption of biosolutions
- Our view on the deep tech that will be instrumental in overcoming these barriers
We’re already developing solutions in our dedicated bio and AI labs, we’ve developed foundational tools, so we can give you a unique viewpoint to help your end-to-end biosolution journey.
